

## Freedom of Information request 48-23

---

### Request & Response

1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:
  - a. Adalimumab - Humira - <5 patients
  - b. Adalimumab Biosimilar - 30 patients
  - c. Apremilast – Not held
  - d. Bimekizumab - 0
  - e. Brodalumab - <5 patients
  - f. Certolizumab - <5 patients
  - g. Dimethyl fumarate (number unknown as no database for this)
  - h. Etanercept - Enbrel (number unknown as no database for this)
  - i. Etanercept Biosimilar (number unknown as no database for this)
  - j. Guselkumab - <5 patients
  - k. Infliximab - Remicade - <5 patients
  - l. Infliximab Biosimilar - 0 patients
  - m. Ixekizumab - <5 patients
  - n. Risankizumab - 15 patients
  - o. Secukinumab - 5 patients
  - p. Tildrakizumab - 14 patients
  - q. Ustekinumab - <5 patients
  
2. How many patients were treated in the last 3 months by the Dermatology department for Hidradenitis Suppurativa (HS) ONLY with the following biologic drugs:
  - a. Adalimumab - Humira - 0 patients
  - b. Adalimumab Biosimilar - <5 patients
  - c. Infliximab - Remicade - 0 patients
  - d. Infliximab Biosimilar - 0 patients
  - e. Secukinumab - 0 patients
  - f. Ustekinumab - <5 patients
  
3. How many patients were treated in the last 3 months by the Dermatology department for Psoriasis ONLY in the last three months with the following:
  - a. Ciclosporin – not held
  - b. Methotrexate - any form and strength – not held
  - c. Methotrexate injections 15mg and above – not held

Some data cannot be provided as this is not held by NHS Borders under Section 17 of the FOI(S)A 2002.

As the number of events in some areas are very small and in accordance with the Code of Practice for Official Statistics any number that is less than five, actual numbers and potentially identifiable information is withheld to help maintain patient confidentiality due to potential risk of disclosure. Further information is available in the [ISD Statistical Disclosure Control Protocol](#).

If you are not satisfied with the way your request has been handled or the decision given, you may ask NHS Borders to review its actions and the decision. If you would like to request a review please apply in writing to,

Freedom of Information Review, NHS Borders, Room 2EC3, Education Centre, Borders General Hospital, Melrose, TD6 9BS or [foi.enquiries@borders.scot.nhs.uk](mailto:foi.enquiries@borders.scot.nhs.uk).

The request for a review should include your name and address for correspondence, the request for information to which the request relates and the issue which you wish to be reviewed. Please state the reference number **48-23** on this request. Your request should be made within 40 working days from receipt of this letter.

If following this review, you remain dissatisfied with the outcome, you may appeal to the Scottish Information Commissioner and request an investigation of your complaint. Your request to the Scottish Information Commissioner should be in writing (or other permanent form), stating your name and an address for correspondence. You should provide the details of the request and your reasons for dissatisfaction with both the original response by NHS Borders and your reasons for dissatisfaction with the outcome of the internal review. Your application for an investigation by the Scottish Information Commissioner must be made within six months of your receipt of the response with which you are dissatisfied. The address for the Office of the Scottish Information Commissioner is, Office of the Scottish Information Commissioner, Kinburn Castle, Doubledykes Road, St Andrews, Fife.